Investor Presentaiton

MYK-224 Cardiovascular milvexian Camzyos Expanding myosin inhibitor franchise in HCM and HFPEF Today CAMZYOS™ (mavacamten) capsules Strong launch momentum enabling more oHCM patients to benefit from Camzyos Medium-Term Expansion into nHCM & opportunity to expand diagnosis rates with Artificial Intelligence supported technology Long-Term Potential opportunity for myosin inhibitors in HFpEF Continued evolution of data suggests disease modifying ability of Camzyos Ill Bristol Myers Squibb™ Not for Product Promotional Use 119

View entire presentation